人工多能性幹細胞（iPSC）の世界市場の機会と2032年までの戦略Including：1) 由来細胞タイプ別肝細胞; 繊維芽細胞; ケラチノサイト; 羊膜細胞2) 用途別：用途別：学術研究、創薬・毒性研究、再生医療、細胞・遺伝子治療3）エンドユーザー別：病院、研究所富士フイルムホールディングス（FUJIFILM Cellular Dynamics, Inc）、サーモフィッシャーサイエンティフィック（Thermo Fisher Scientific, Inc）、タカラバイオ（Takara Bio, Inc）、ロンザグループ（Lonza Group AG）、アステラス製薬（Astellas Pharma Inc

Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2032Including: 1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell And Gene Therapy3) By End-User: Hospitals; Research LaboratoriesCovering: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group AG; Astellas Pharma Inc

この調査レポートは、世界の人工多能性幹細胞（iPSC）市場がCOVID-19の閉鎖から脱却する際に必要な重要情報を提供しています。購入の理由 - 12地域をカバーするこの市場に関する最も包括的なレポートにより... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Business Research Company　(TBRC) ザ・ビジネスリサーチカンパニー	2023年4月25日	US$5,000 シングルユーザライセンスライセンス・価格情報注文方法はこちら	310	英語

サマリー

この調査レポートは、世界の人工多能性幹細胞（iPSC）市場がCOVID-19の閉鎖から脱却する際に必要な重要情報を提供しています。

購入の理由
- 12地域をカバーするこの市場に関する最も包括的なレポートにより、真にグローバルな視点を得ることができます。
- 市場がコロナウイルスによってどのような影響を受けているのか、また、ウイルスの影響が和らぐにつれて市場がどのように出現し、成長する可能性があるのかを理解する。
- 現地のデータと分析に基づき、地域別および国別の戦略を策定します。
- 投資の対象となる成長セグメントを特定する。
- 予測データと市場を形成するドライバーとトレンドを活用し、競合他社を凌駕する。
- 最新の市場調査結果に基づいて顧客を理解する。
- 主要な競合他社とのパフォーマンスの比較
- 主要データセット間の関係を活用し、優れた戦略を立てる。
- 信頼性の高い高品質なデータと分析により、社内外のプレゼンテーションをサポートします。

説明
人工多能性幹細胞（iPSC）の市場が最も大きく、急成長しているのはどこか？この市場は経済全体、人口動態、他の類似市場とどのように関連しているのか？今後の市場を形成する力は何か？The Business Research Companyの人工多能性幹細胞（iPSC）世界市場レポートでは、これらすべての疑問やその他多くの疑問にお答えします。

当レポートでは、市場の特徴、規模および成長、セグメンテーション、地域別および国別内訳、競合情勢、市場シェア、市場の動向および戦略について記載しています。地域別に市場の過去および予測成長を追跡しています。人工多能性幹細胞（iPSC）市場全体の中で同市場を位置づけ、他市場との比較も行っています。

本レポートは以下の章をカバーしています：
- 序論と市場の特徴
人工多能性幹細胞（iPSC）市場について、市場細分化、定義、解説を簡単に紹介しています。
- 主要動向
世界の人工多能性幹細胞（iPSC）市場を形成している主要トレンドをハイライト。また、今後の市場動向についても取り上げます。
- 世界の市場規模と成長
世界の過去（2017年～2022年）、予測（2022年～2027年）、（2027年～2032年）市場価値、過去および予測期間における市場の成長を支え、制御する推進要因と阻害要因。
- 地域別分析
地域別の過去（2017-2022年）および予測（2022-2027年）、（2027-2032年）市場価値と成長率、市場シェア比較。
- 市場セグメンテーション
市場における派生細胞タイプ別、用途別、エンドユーザー別の市場価値（2017-2032）と各セグメント別の分析を収録。
- 地域別市場規模と成長
地域別の市場規模（2022年）、過去（2017年～2022年）および予測（2022年～2027年）、（2027年～2032年）の市場価値、地域内各国の成長率と市場シェア比較。本レポートには、アジア太平洋、西欧、東欧、北米、南米、中東、アフリカの全地域と各地域内の主要国に関する情報が含まれています。
- 競争環境
市場の競争状況、推定市場占有率、主要企業の会社プロファイルの詳細を掲載しています。
- 主要なM&A
本レポートでカバーしている市場における最近のM&Aに関する情報を掲載しています。本セクションでは、近年の市場を形成したM&Aに関する主要な財務情報を掲載しています。
- 市場機会と戦略
調査結果に基づく市場機会と戦略について、国やセグメントごとの成長機会や、それらの市場で取るべき戦略に関する情報を交えて記述しています。
- 結論と提言
人工多能性幹細胞（iPSC）プロバイダーに対する、製品・サービスの提供地域拡大、マーケティング戦略、ターゲットグループに関する推奨事項を記載しています。
- 付録
このセクションには、本レポートで使用されているNAICSコード、略語、通貨コードの詳細が含まれています。

スコープ

対象市場
1) 由来細胞タイプ別：肝細胞；線維芽細胞；ケラチノサイト；羊膜細胞；その他の由来細胞タイプ
2) 用途別学術研究；創薬・毒性研究；再生医療；細胞・遺伝子治療
3) エンドユーザー別：病院；研究所

言及された企業富士フイルムホールディングス株式会社（富士フイルムセルラーダイナミクス株式会社）、サーモフィッシャーサイエンティフィック株式会社、タカラバイオ株式会社、ロンザグループ株式会社、アステラス製薬株式会社

国中国、オーストラリア、インド、インドネシア、日本、韓国、アメリカ、ブラジル、フランス、ドイツ、イギリス、ロシア

地域アジア太平洋; 西ヨーロッパ; 東ヨーロッパ; 北アメリカ; 南アメリカ; 中東; アフリカ

時系列：過去5年間および過去10年間の予測。

データ関連市場に対する市場規模および成長率、GDP比率、一人当たり支出、人工多能性幹細胞（iPSC）指標の比較。

データ区分：国別・地域別の過去データと予測データ、競合他社の市場シェア、市場セグメント。

ソーシングと参照：本レポート中のデータおよび分析は、エンドノートを使用しています。

当レポートでは、人工多能性幹細胞（iPSC）市場について記載・解説し、2017-2022年を過去期間、2022-2027年を予測期間とし、さらに2027-2032年の予測を加えています。本レポートでは、各地域および各地域内の主要経済圏における市場を評価している。

世界の人工多能性幹細胞（iPSC）市場は、2017年以降、年平均成長率（CAGR）10.7％で増加し、2022年には約26億8630万ドルに達した。同市場は、2022年の26億8630万ドルから2027年には43億6370万ドルまで10.2%の成長率で拡大すると予想されている。その後、2027年からCAGR 9.2%で成長し、2032年には67億6,340万ドルに達すると予想される。

歴史的期間の成長は、医療費の増加、資金調達の増加、幹細胞製品の医薬品としての可能性に対する認識の高まり、人工多能性幹細胞（iPSC）を利用した創薬、個別化医療に対する需要の高まり、創薬におけるiPSCの費用対効果の高さなどに起因している。しかし、人工多能性幹細胞に対する認知度の低さ、関連コストの高さ、技術的な限界、長いプロセス、不十分な保険償還などが、過去における成長にマイナスの影響を与えた要因であった。

今後は、慢性疾患の増加、ゲノムプロジェクトの増加、iPS細胞由来の疾患モデルの開発、遺伝性疾患の有病率の増加、政府の取り組み、技術の急速な向上が市場を牽引していくだろう。今後の人工多能性幹細胞（iPSC）市場の成長を阻害する要因としては、iPSC製造の自動化、人工多能性幹細胞治療に伴うリスク、ロシア・ウクライナ戦争やコロナウイルスの大流行による医療施設の混乱、保管コストの高さなどが挙げられる。

人工多能性幹細胞（iPSC）市場は、由来細胞タイプ別に肝細胞、線維芽細胞、ケラチノサイト、羊膜細胞、その他の由来細胞タイプに区分される。線維芽細胞は、人工多能性幹細胞（iPSC）市場の派生細胞タイプ別で最大のセグメントであり、2022年の市場全体の29.5％にあたる7億9270万ドルを占めた。その他の由来細胞タイプ市場は、CAGR 10.7%で今後最も急成長するセグメントと予想される。

人工多能性幹細胞（iPSC）市場は、用途別に学術研究、創薬・毒性研究、再生医療、細胞・遺伝子治療に区分される。創薬・毒性試験市場は、人工多能性幹細胞（iPSC）市場の用途別最大セグメントで、2022年には12億9480万ドル、市場全体の48.2％を占めた。細胞・遺伝子治療市場は、CAGR11.7%で今後最も急成長する分野と予想される。

人工多能性幹細胞（iPSC）市場は、エンドユーザー別に病院と研究所に区分される。研究室は、人工多能性幹細胞（iPSC）市場のエンドユーザー別で最大のセグメントであり、2022年には市場全体の86.0%にあたる18億2630万ドルを占めた。病院市場はCAGR 11.0%で今後最も急成長するセグメントと予想される。

人工多能性幹細胞（iPSC）市場で最大の地域は北米で、2022年の世界市場の47.7％を占めた。次いで西ヨーロッパ、アジア太平洋、その他の地域と続く。今後、人工多能性幹細胞（iPSC）市場で急成長する地域は南米と中東で、2022-2027年の年平均成長率はそれぞれ31.3%と29.6%である。

人工多能性幹細胞（iPSC）市場は断片化されており、多数のプレーヤーが存在する。同市場における上位10社の競争力は、2021年には市場全体の27.50%を占めている。富士フイルムホールディングス（FUJIFILM Cellular Dynamics, Inc）が市場シェア10.46%で最も大きく、次いでThermo Fisher Scientific, Incが6.43%、Takara Bio, Incが3.78%、Lonza Group AGが2.81%、Astellas Pharma Incが1.51%、ViaCyte, Incが0.90%、Ncardiaが0.70%、REPROCELL USA, Incが0.62%、Japan Tissue Engineering Co、Ltd.が0.24%、Merck KGaAが0.05%であった。

人工多能性幹細胞（iPSC）市場の派生細胞タイプ別では、線維芽細胞市場に最大のビジネスチャンスがあり、2027年までに世界全体の年間売上高が4億9510万ドルに達する見込みである。人工多能性幹細胞（iPSC）市場の用途別では、創薬・毒性試験市場に大きなビジネスチャンスがあり、2027年までに世界全体の年間売上高が7億6,190万ドルに達するだろう。人工多能性幹細胞（iPSC）市場のエンドユーザー別では、2027年までに世界全体の年間売上高が10億8540万ドルに達する研究施設市場に大きなビジネスチャンスが生まれるだろう。人工多能性幹細胞（iPSC）市場規模は、米国で2億6780万ドルと最も大きく成長する。

人工多能性幹細胞（iPSC）市場の市場動向に基づく戦略としては、パーキンソン病（PD）用多能性幹細胞の開発、戦略的共同研究・提携、人工多能性幹細胞iPSC由来NK細胞の開発、細胞治療用人工多能性幹細胞（iPSC）の開発、再生医療研究開発への投資、iPSC膨張培地の開発、個別化iPSCの開発、I型糖尿病用多能性幹細胞の開発などが挙げられる。

人工多能性幹細胞（iPSC）業界におけるプレーヤー採用の戦略には、事業能力の拡大による細胞治療事業の強化、新製品の上市による患者ケアの未来変革への注力、戦略的契約によるiPSCのエンド・ツー・エンドの独自サービス提供の強化が含まれる。

ビジネス・リサーチ・カンパニーは、このような機会を活用するため、人工多能性幹細胞（iPSC）企業に対し、パーキンソン病（PD）向け多能性幹細胞の開発に注力すること、人工多能性幹細胞iPSC由来ナチュラルキラー（NK）細胞に注力すること、細胞治療に注力すること、iPSC拡大培地に注力すること、個別化iPSCに注力することを推奨する、1型糖尿病用多能性幹細胞への注力、新興市場での事業拡大、先進国市場への注力の継続、パートナーシップと提携への注力、価格競争力のある製品の提供、見本市やイベントへの参加、B2Bプロモーションの継続、急成長するエンドユーザーをターゲットにする、急成長するアプリケーションをターゲットにする、高齢者人口をターゲットにする。

ページTOPに戻る

1. Executive Summary
2. Table Of Contents
3. List Of Figures
4. List Of Tables
5. Report Structure
6. Introduction And Market Characteristics
6.1. General Market Definition
6.2. Summary
6.3. Induced Pluripotent Stem Cell (iPSC) Market Definition And Segmentations
6.4. Market Segmentation By Derived Cell Type
6.4.1. Blood Cells
6.4.2. Hepatocytes
6.4.3. Fibroblasts
6.4.4. Keratinocytes
6.4.5. Amniotic Cells
6.4.6. Other Derived Cell Types
6.5. Market Segmentation By Application
6.5.1. Academic Research
6.5.2. Drug Discovery And Toxicity Studies
6.5.3. Regenerative Medicine
6.5.4. Cell And Gene Therapy
6.6. Market Segmentation By End-User
6.6.1. Hospitals
6.6.2. Research Laboratories
7. Major Market Trends
7.1. Development of Pluripotent Stem Cells For Parkinson’s Disease (PD)
7.2. Strategic Collaborations And Partnerships
7.3. Induced Pluripotent Stem Cell iPSC-Derived NK Cells
7.4. Induced Pluripotent Stem Cell (iPSC) For Cell Therapy
7.5. Investment In Regenerative Medicine Research And Development
7.6. Development of iPSC Expansion Medium
7.7. Personalized iPSC
7.8. Pluripotent Stem Cells For Type I Diabetes
8. Global Market Size and Growth
8.1. Market Size
8.2. Historic Market Growth, 2017 – 2022, Value ($ Million)
8.2.1. Market Drivers 2017 – 2022
8.2.2. Market Restraints 2017 – 2022
8.3. Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
8.3.1. Market Drivers 2022 – 2027
8.3.2. Market Restraints 2022 – 2027
9. Global Induced Pluripotent Stem Cell (iPSC) Market Segmentation
9.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
9.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
9.3. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
10. Induced Pluripotent Stem Cell (iPSC) Market, Regional and Country Analysis
10.1. Global Induced Pluripotent Stem Cell (iPSC) Market, By Region, Historic and Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
10.2. Global Induced Pluripotent Stem Cell (iPSC) Market, By Country, Historic and Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11. Asia-Pacific Market
11.1. Summary
11.2. Market Overview
11.2.1. Region Information
11.2.2. Market Information
11.2.3. Background Information
11.2.4. Government Initiatives
11.2.5. Regulations
11.2.6. Regulatory Bodies
11.2.7. Major Associations
11.2.8. Taxes levied
11.2.9. Corporate Tax Structure
11.2.10. Investments
11.2.11. Major Companies
11.3. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.4. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.5. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.6. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.7. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis
11.9. China Market
11.10. Summary
11.11. Market Overview
11.11.1. Country Information
11.11.2. Market Information
11.11.3. Background Information
11.11.4. Government Initiatives
11.11.5. Regulations
11.11.6. Regulatory Bodies
11.11.7. Major Associations
11.11.8. Taxes levied
11.11.9. Corporate tax structure
11.11.10. Investments
11.11.11. Major Companies
11.12. China Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.13. China Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.14. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.15. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.16. China Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.17. India Market
11.18. India Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.19. India Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.20. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.21. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.22. India Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.23. Japan Market
11.24. Japan Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.25. Japan Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.26. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.27. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.28. Japan Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.29. Australia Market
11.30. Australia Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.31. Australia Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.32. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.33. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.34. Australia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.35. Indonesia Market
11.36. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.37. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.38. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.39. Indonesia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.40. South Korea Market
11.41. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
11.42. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
11.43. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.44. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
11.45. South Korea Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12. Western Europe Market
12.1. Summary
12.2. Market Overview
12.2.1. Region Information
12.2.2. Market Information
12.2.3. Background Information
12.2.4. Government Initiatives
12.2.5. Regulations
12.2.6. Regulatory Bodies
12.2.7. Major Associations
12.2.8. Taxes levied
12.2.9. Corporate tax structure
12.2.10. Investments
12.2.11. Major Companies
12.3. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
12.4. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
12.5. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.6. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.7. Western Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.8. Western Europe Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis
12.9. UK Market
12.10. UK Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
12.11. UK Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
12.12. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.13. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.14. UK Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.15. Germany Market
12.16. Germany Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
12.17. Germany Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
12.18. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.19. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.20. Germany Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.21. France Market
12.22. France Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
12.23. France Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
12.24. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.25. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
12.26. France Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13. Eastern Europe Market
13.1. Summary
13.2. Market Overview
13.2.1. Region Information
13.2.2. Market Information
13.2.3. Background Information
13.2.4. Government Initiatives
13.2.5. Regulations
13.2.6. Regulatory Bodies
13.2.7. Major Associations
13.2.8. Taxes Levied
13.2.9. Corporate Tax Structure
13.2.10. Investments
13.2.11. Major Companies
13.3. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
13.4. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
13.5. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13.6. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13.7. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13.8. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis
13.9. Russia Market
13.10. Russia Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
13.11. Russia Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
13.12. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13.13. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
13.14. Russia Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14. North America Market
14.1. Summary
14.2. Market Overview
14.2.1. Region Information
14.2.2. Market Information
14.2.3. Background Information
14.2.4. Government Initiatives
14.2.5. Regulations
14.2.6. Regulatory Bodies
14.2.7. Major Associations
14.2.8. Taxes Levied
14.2.9. Corporate Tax Structure
14.2.10. Investments
14.2.11. Major Companies
14.3. North America Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
14.4. North America Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
14.5. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14.6. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14.7. North America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14.8. North America Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis
14.9. USA Market
14.10. Summary
14.11. Market Overview
14.11.1. Country Information
14.11.2. Market Information
14.11.3. Background Information
14.11.4. Government Initiatives
14.11.5. Regulations
14.11.6. Regulatory Bodies
14.11.7. Major Associations
14.11.8. Taxes Levied
14.11.9. Corporate Tax Structure
14.11.10. Investments
14.11.11. Major Companies
14.12. USA Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
14.13. USA Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
14.14. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14.15. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
14.16. USA Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15. South America Market
15.1. Summary
15.2. Market Overview
15.2.1. Region Information
15.2.2. Market Information
15.2.3. Background Information
15.2.4. Government Initiatives
15.2.5. Regulations
15.2.6. Regulatory Bodies
15.2.7. Major Associations
15.2.8. Taxes Levied
15.2.9. Corporate Tax Structure
15.2.10. Investments
15.2.11. Major Companies
15.3. South America Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
15.4. South America Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
15.5. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15.6. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15.7. South America Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15.8. South America Induced Pluripotent Stem Cell (iPSC) Market: Country Analysis
15.9. Brazil Market
15.10. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
15.11. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
15.12. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15.13. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
15.14. Brazil Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
16. Middle East Market
16.1. Summary
16.2. Market Overview
16.2.1. Region Information
16.2.2. Market Information
16.2.3. Background information
16.2.4. Government Initiatives
16.2.5. Regulations
16.2.6. Regulatory bodies
16.2.7. Taxes Levied
16.2.8. Corporate Tax Structure
16.2.9. Major Associations
16.2.10. Investments
16.2.11. Major Companies
16.3. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Historic Market Growth, 2017 – 2022, Value ($ Million)
16.4. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
16.5. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
16.6. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
16.7. Middle East Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
17. Africa Market
17.1. Summary
17.2. Market Overview
17.2.1. Region Information
17.2.2. Market Information
17.2.3. Background Information
17.2.4. Government Initiatives
17.2.5. Regulations
17.2.6. Regulatory bodies
17.2.7. Major Associations
17.2.8. Taxes Levied
17.2.9. Corporate Tax Structure
17.2.10. Investments
17.2.11. Major Companies
17.3. Africa Induced Pluripotent Stem Cell (iPSC) Market, Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
17.4. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
17.5. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
17.6. Africa Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-User, Historic And Forecast, 2017 – 2022, 2027F, 2032F, Value ($ Million)
18. Competitive Landscape and Company Profiles
18.1. Company Profiles
18.2. FUJIFILM Holdings Corporation
18.2.1. Company Overview
18.2.2. Products And Services
18.2.3. Business Strategy
18.2.4. Financial Overview
18.3. Thermo Fisher Scientific, Inc
18.3.1. Company Overview
18.3.2. Products And Services
18.3.3. Business Strategy
18.3.4. Financial Overview
18.4. Takara Bio, Inc
18.4.1. Company Overview
18.4.2. Products And Services
18.4.3. Business Strategy
18.4.4. Financial Overview
18.5. Lonza Group AG
18.5.1. Company Overview
18.5.2. Products And Services
18.5.3. Business Strategy
18.5.4. Financial Overview
18.6. Astellas Pharma Inc
18.6.1. Company Overview
18.6.2. Products And Services
18.6.3. Business Strategy
18.6.4. Financial Overview
19. Key Mergers and Acquisitions
19.1. Century Therapeutics Collaborated With Bristol Myers Squibb
19.2. CellOrigin Biotech Collaborated With Qilu Pharmaceutical
19.3. Evotec Acquired Rigenerand
19.4. Vertex Pharmaceuticals Acquired ViaCyte
19.5. Medipost Acquired OmniaBio
19.6. Catalent Acquired RheinCell Therapeutics
20. Opportunities And Strategies
20.1. Global Induced Pluripotent Stem Cell (iPSC) Market In 2027 – Countries Offering Most New Opportunities
20.2. Global Induced Pluripotent Stem Cell (iPSC) Market In 2027 – Segments Offering Most New Opportunities
20.3. Global Induced Pluripotent Stem Cell (iPSC) Market In 2027 – Growth Strategies
20.3.1. Market Trend Based Strategies
20.3.2. Competitor Strategies
21. Induced Pluripotent Stem Cell (iPSC) Market, Conclusions And Recommendations
21.1. Conclusions
21.2. Recommendations
21.2.1. Product
21.2.2. Place
21.2.3. Price
21.2.4. Promotion
21.2.5. People
22. Appendix
22.1. Market Data Sources
22.2. Research Methodology
22.3. Currencies
22.4. The Business Research Company
22.5. Copyright and Disclaimer

ページTOPに戻る

Table of Contents

Summary

Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2032 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global induced pluripotent stem cell (iPSC) market as it emerges from the COVID-19 shut down.

Reasons to Purchase
• Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:
Where is the largest and fastest growing market for induced pluripotent stem cell (iPSC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cell (iPSC) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider induced pluripotent stem cell (iPSC) market; and compares it with other markets.

The report covers the following chapters:
• Introduction and Market Characteristics
Brief introduction to the segmentations covered in the market, definitions and explanations about the induced pluripotent stem cell (iPSC) market.
• Key Trends
Highlights the major trends shaping the global induced pluripotent stem cell (iPSC) market. This section also highlights likely future developments in the market.
• Global Market Size and Growth
Global historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional Analysis
Historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values and growth and market share comparison by region.
• Market Segmentation
Contains the market values (2017-2032) and analysis for each segment by derived cell type, by application and by end-user in the market.
• Regional Market Size and Growth
Regional market size (2022), historic (2017-2022) and forecast (2022-2027), and (2027-2032) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape
Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Key Mergers and Acquisitions
Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Market Opportunities And Strategies
Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations
This section Includes recommendations for induced pluripotent stem cell (iPSC) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix
This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope:

Markets Covered:
1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cell Types
2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell And Gene Therapy
3) By End-User: Hospitals; Research Laboratories

Companies Mentioned: Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics, Inc); Thermo Fisher Scientific, Inc; Takara Bio, Inc; Lonza Group Ag; Astellas Pharma Inc.

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; induced pluripotent stem cell (iPSC) indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,686.3 million in 2022, having increased at a compound annual growth rate (CAGR) of 10.7% since 2017. The market is expected to grow from $2,686.3 million in 2022 to $4,363.7 million in 2027 at a rate of 10.2%. The market is then expected to grow at a CAGR of 9.2% from 2027 and reach $6,763.4 million in 2032.

Growth in the historic period resulted from increasing healthcare expenditure, a rise in funding, rising awareness of stem cell products' medicinal potential, use of induced pluripotent stem cell (iPSC) based drug discovery, increasing demand for personalized medicine and cost-effective benefits of iPSC for drug discovery. Factors that negatively affected growth in the historic period were a lack of awareness on induced pluripotent stem cell, high associated costs, technical limitations and lengthy process and inadequate reimbursements.

Going forward, an increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology will drive the market. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include automation of iPSC production, the risk associated with induced pluripotent stem cell treatment, disruption of medical facilities due to the Russia-Ukraine war and the coronavirus pandemic and high storage cost.

The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and other derived cell types. The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market by derived cell type, accounting for $792.7 million or 29.5% of the total market in 2022. The other derived cell types market is expected to be the fastest-growing segment going forward at a CAGR of 10.7%.

The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine, and cell and gene therapy. The drug discovery and toxicity studies market was the largest segment of the induced pluripotent stem cell (iPSC) market by application, accounting for $1,294.8 million or 48.2% of the total market in 2022. The cell and gene therapy market is expected to be the fastest-growing segment going forward at a CAGR of 11.7%.

The induced pluripotent stem cell (iPSC) market is segmented by end-users into hospitals and research laboratories. The research laboratories was the largest segment of the induced pluripotent stem cell (iPSC) market by end-users, accounting for $1,826.3 million or 86.0% of the total market in 2022. The hospitals market is expected to be the fastest-growing segment going forward at a CAGR of 11.0%.

North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 47.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the induced pluripotent stem cell (iPSC) market will be South America and Middle East, where growth will be at CAGRs of 31.3% and 29.6%respectively from 2022-2027.

The induced pluripotent stem cell (iPSC) market is fragmented, with a large number of players. The top ten competitors in the market made up to 27.50% of the total market in 2021. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with 10.46% share of the market, followed by Thermo Fisher Scientific, Inc with 6.43%, Takara Bio, Inc with 3.78%, Lonza Group AG with 2.81%, Astellas Pharma Inc with 1.51%, ViaCyte, Inc with 0.90%, Ncardia with 0.70%, REPROCELL USA, Inc with 0.62%, Japan Tissue Engineering Co., Ltd with 0.24%, and Merck KGaA with 0.05%.

The top opportunities in the induced pluripotent stem cell (iPSC) market by derived cell type will arise in the fibroblasts market, which will gain $495.1 million of global annual sales by 2027. The top opportunities in the induced pluripotent stem cell (iPSC) market by application will arise in the drug discovery and toxicity studies market, which will gain $761.9 million of global annual sales by 2027. The top opportunities in the induced pluripotent stem cell (iPSC) market by end-users will arise in research laboratories market, which will gain $1,085.4 million of global annual sales by 2027. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $267.8 million.

Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include development of pluripotent stem cells for Parkinson’s disease (PD), strategic collaborations and partnerships, development of induced pluripotent stem cell iPSC-derived NK cells, development of induced pluripotent stem cell (iPSC) for cell therapy, investment in regenerative medicine research and development, development of iPSC expansion medium, development of personalized iPSC and development of pluripotent stem cells for type I diabetes.

Player-adopted strategies in the induced pluripotent stem cell (iPSC) industry include focus on strengthening cell therapies business through expanding operational capabilities, focus on transforming the future of patient care through new product launches and focus on strengthening end-to-end proprietary service offering for iPSCs through strategic agreements.

To take advantage of the opportunities, The Business Research Company recommends the induced pluripotent stem cell (iPSC) companies to focus on development of pluripotent stem cells for Parkinson’s disease (PD), focus on induced pluripotent stem cell iPSC-derived natural killer (NK) cells, focus on cell therapy, focus on iPSC expansion medium, focus on personalized iPSC, focus on pluripotent stem cells for type 1 diabetes, expand in emerging markets, continue to focus on developed markets, focus on partnerships and collaborations, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, target fast-growing end-users, continue to target fast-growing applications and target the elderly population.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

The Business Research Company　(TBRC)社の医療サービス分野での最新刊レポート

本レポートと同じKEY WORD（amniotic）の最新刊レポート

よくあるご質問

The Business Research Company　(TBRC)社はどのような調査会社ですか?

The Business Research Company (TBRC)はインドを主要拠点に世界の多様な市場を調査・予測し、調査レポートを積極的に出版しています。調査対象には技術、ライフサイエンス、重... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

The Business Research Company (TBRC)社の医療サービス分野での最新刊レポート

本レポートと同じKEY WORD（amniotic）の最新刊レポート

よくあるご質問

The Business Research Company (TBRC)社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?

The Business Research Company　(TBRC)社の医療サービス分野での最新刊レポート

The Business Research Company　(TBRC)社はどのような調査会社ですか?